ZOLGENSMA Kit Patient Weight 14.6 - 15.0 KG

RxCUI: 2630839
RxNorm name: ZOLGENSMA Kit Patient Weight 14.6 - 15.0 KG
Display name: ZOLGENSMA Kit Patient Weight 14.6 - 15.0 KG
Full name: ZOLGENSMA Kit Patient Weight 14.6 - 15.0 KG
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:02

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
125694	Zolgensma	onasemnogene abeparvovec-xioi	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Zolgensma	ONASEMNOGENE ABEPARVOVEC-XIOI	Novartis Innovative Technologies Inc.	68cd4f06-70e1-40d8-bedb-609ec0afa471	2026-06-16	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2630839

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
68cd4f06-70e1-40d8-bedb-609ec0afa471	{10 (8.3 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection [Zolgensma]) } Pack [Zolgensma Kit 14.6 - 15.0 kg] [BPCK] · ZOLGENSMA Kit Patient Weight 14.6 - 15.0 KG [PSN] · Zolgensma Kit Patient Weight 14.6 - 15.0 KG [SY]	3	14	These highlights do not include all the information needed to use ZOLGENSMA safely and effectively. See full prescribing information for ZOLGENSMA. ZOLGENSMA ® (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion Initial U.S. Approval: 2019	20251218